Abo Bibliothek: Guest
Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen
Critical Reviews™ in Therapeutic Drug Carrier Systems
Impact-faktor: 2.9 5-jähriger Impact-Faktor: 3.72 SJR: 0.736 SNIP: 0.818 CiteScore™: 4.6

ISSN Druckformat: 0743-4863
ISSN Online: 2162-660X

Volumes:
Volumen 37, 2020 Volumen 36, 2019 Volumen 35, 2018 Volumen 34, 2017 Volumen 33, 2016 Volumen 32, 2015 Volumen 31, 2014 Volumen 30, 2013 Volumen 29, 2012 Volumen 28, 2011 Volumen 27, 2010 Volumen 26, 2009 Volumen 25, 2008 Volumen 24, 2007 Volumen 23, 2006 Volumen 22, 2005 Volumen 21, 2004 Volumen 20, 2003 Volumen 19, 2002 Volumen 18, 2001 Volumen 17, 2000 Volumen 16, 1999 Volumen 15, 1998 Volumen 14, 1997 Volumen 13, 1996 Volumen 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.2017018714
pages 1-64

Polymeric Immunonanoparticles Mediated Cancer Therapy: Versatile Nanocarriers for Cell-Specific Cargo Delivery

Namdev L. Dhas
Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat, India
Ritu R. Kudarha
Faculty of Pharmacy, The Maharaja Sayajirao University of Baroda, Vadodara, Gujarat, India
Niyati S. Acharya
Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat, India
Sanjeev R. Acharya
SSR College of Pharmacy, Sayli, Silvassa, Dadra Nagar and Haveli, India

ABSTRAKT

The major drawback with conventional therapeutic approaches for cancer therapy is decreased efficacy and redundant therapy associated toxicity and side effects causing increased patient discomfort. With the aim of minimizing these limitations, a vast amount of attention has been given to targeted nanocarrier–based drug delivery systems that possess a several-fold advantage over conventional therapy. Increased research in targeted nanoparticulate systems has led to the development of immunonanoparticles with enhanced efficacy and targeting efficiency along with decreased drug-resistant cancer- and dose-related toxicity. These immunonanoparticle- based therapies, which can be extended to immunotherapy, have gained wide attention, but few formulations will be approved by regulatory agencies in the near future. This review details the various immunonanoparticle systems explored in cancer therapy, with particular emphasis on polymeric nanoparticles. This review describes the mechanisms of immunotherapy and the pathways for targeting dendritic cells for immunotherapy. It also focuses on present status of clinical trials of immunonanoparticles and related patents, as well as various FDA-approved monoclonal antibodies (mAbs) for immunotherapy. Toxicity issues related to immunonanoparticles along with regulatory guidelines for these therapeutic nanoparticles are also discussed.


Articles with similar content:

Delivery of Biotherapeutics by Inhalation Aerosol
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.12, 1995, issue 2-3
Ralph W. Niven
Recent Advances in Nanoparticle-Based Targeted Drug-Delivery Systems Against Cancer and Role of Tumor Microenvironment
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.34, 2017, issue 4
Usman Ali Ashfaq, Muhammad Zubair Yousaf, Erum Yasmeen, Muhammad Riaz
Innovative Drug Delivery Strategies for Topical Photodynamic Therapy using Porphyrin Precursors
Journal of Environmental Pathology, Toxicology and Oncology, Vol.26, 2007, issue 2
Martin J. Garland, Desmond I. J. Morrow, Paul A. McCarron, Ryan F. Donnelly, A. David Woolfson
Progress in Lipid-Based Nanoparticles for Cancer Therapy
Critical Reviews™ in Oncogenesis, Vol.19, 2014, issue 3-4
Eliahu Heldman, Charles Linder, Sarina Grinberg
Bacterial Toxins in Cancer Immunotherapy
Forum on Immunopathological Diseases and Therapeutics, Vol.4, 2013, issue 3-4
Lenka Sadilkova, Irena Adkins, Lenka Palova-Jelinkova